Xwell (XWEL) Amortization of Deferred Charges (2015 - 2026)

Xwell (XWEL) posted Amortization of Deferred Charges of $85000.0 for Q1 2026, down 65.45% sequentially from $246000.0 in Q1 2025, and down 65.45% YoY from $246000.0 in Q1 2025.

Xwell (XWEL) Amortization of Deferred Charges (2015 - 2026) Analysis & Trends

Xwell has reported Amortization of Deferred Charges for 7 years, with the latest figure at $85000.0 in Q1 2026.

  • Quarterly Amortization of Deferred Charges fell 65.45% year-over-year to $85000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $340000.0 (up 20.57% YoY) and the FY2025 annual result came in at $916000.0, down 31.39% from the prior year.
  • Amortization of Deferred Charges eased to $85000.0 in Q1 2026 per XWEL's latest filing, from $246000.0 in the prior quarter.
  • Over five years, Amortization of Deferred Charges peaked at $246000.0 in Q1 2025 and troughed at $85000.0 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Thermo Fisher Scientific 213.88 Bn 209.81 Bn 8.34 Bn
2 Danaher 140.65 Bn 136.30 Bn 3.61 Bn
3 Idexx Laboratories 46.02 Bn 45.83 Bn 779.09 Mn
4 Agilent Technologies 39.85 Bn 38.05 Bn 990.00 Mn
5 Iqvia Holdings 39.20 Bn 37.12 Bn 1.44 Bn
6 Natera 38.80 Bn 37.70 Bn 696.04 Mn
7 Illumina 30.11 Bn 28.94 Bn 770.00 Mn
8 Mettler Toledo International 28.66 Bn 28.61 Bn 650.22 Mn
9 Quest Diagnostics 26.24 Bn 25.61 Bn 1.03 Bn
10 Xwell 7.47 Mn -9.34 Mn 2.35 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 85,000.00
Mar 31, 2026 85,000.00
Mar 31, 2025 246,000.00
Mar 31, 2025 246,000.00
Dec 31, 2020 3,000.00
Dec 31, 2020 3,000.00
Sep 30, 2020 6,000.00
Sep 30, 2020 6,000.00
Jun 30, 2020 27,000.00
Jun 30, 2020 27,000.00
Mar 31, 2020 87,000.00
Mar 31, 2020 87,000.00
Dec 31, 2019 235,000.00
Dec 31, 2019 235,000.00
Sep 30, 2019 19,000.00
Sep 30, 2019 19,000.00
Jun 30, 2019 342,000.00
Jun 30, 2019 342,000.00
Mar 31, 2019 394,000.00
Mar 31, 2019 394,000.00